Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
AE Wealth Management LLC Purchases New Holdings in Incyte Corporation $INCY
03:11am, Tuesday, 21'st Apr 2026
AE Wealth Management LLC purchased a new stake in Incyte Corporation (NASDAQ: INCY) during the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 26,995 shares of
Here's Why Incyte (INCY) is a Strong Value Stock
10:42am, Monday, 20'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Merit Financial Group LLC Has $4.92 Million Stock Holdings in Incyte Corporation $INCY
05:17am, Monday, 20'th Apr 2026
Merit Financial Group LLC increased its holdings in Incyte Corporation (NASDAQ: INCY) by 41.7% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commis
KBC Group NV Sells 157,700 Shares of Incyte Corporation $INCY
04:36am, Saturday, 18'th Apr 2026
KBC Group NV decreased its position in Incyte Corporation (NASDAQ: INCY) by 37.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Com
Incyte to Report First Quarter Financial Results
08:00am, Thursday, 09'th Apr 2026
WILMINGTON, Del.--(BUSINESS WIRE)--1Q Alert.
Incyte Corporation (NASDAQ:INCY) Given Average Rating of “Hold” by Brokerages
02:39am, Wednesday, 08'th Apr 2026
Incyte Corporation (NASDAQ: INCY - Get Free Report) has received an average recommendation of "Hold" from the twenty-one brokerages that are currently covering the stock, MarketBeat reports. One analy
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
07:05am, Wednesday, 01'st Apr 2026
Oncology M&A activity is accelerating as large pharmaceutical companies race to replenish pipelines facing patent cliffs and seek exposure to next-generation therapeutic platforms.
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study
04:00pm, Monday, 30'th Mar 2026
Incyte's povorcitinib shows sustained 54-week efficacy in HS, with strong response rates and safety profile, reinforcing its potential.
Incyte's skin disease drug shows long-term symptom relief in late-stage trials
03:04pm, Saturday, 28'th Mar 2026
Incyte said on Saturday its experimental skin disease drug showed long-term reduction of symptoms in two late-stage trials.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting.
Diversified Trust Co. Has $1.40 Million Position in Incyte Corporation $INCY
04:26am, Thursday, 26'th Mar 2026
Diversified Trust Co. cut its stake in Incyte Corporation (NASDAQ: INCY) by 37.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fu
Incyte Announces Executive Leadership Appointments
09:00am, Wednesday, 25'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Executive Leadership Appointments.
Incyte: An Undervalued Healthcare Gem
11:11pm, Sunday, 22'nd Mar 2026
Incyte is proactively addressing Jakafi's 2028 patent cliff through robust pipeline diversification and strategic acquisitions. Jakafi delivered $3.09B in 2025 sales, up 11% YoY, underpinning strong o
Incyte Corporation $INCY Shares Sold by JPMorgan Chase & Co.
05:20am, Sunday, 22'nd Mar 2026
JPMorgan Chase and Co. lessened its stake in Incyte Corporation (NASDAQ: INCY) by 46.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The insti
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
10:00am, Friday, 20'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #AAD2026--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting.
